Polyprotein Malaria Vaccine FP9 PP and MVA
A Plasmodium falciparum Candidate Vaccine Based on a Six Antigen Polyprotein Encoded by Recombinant Poxviruses
The cGMP production of clinical batches of vaccine and fowlpox constructs was performed by IDT in Germany.
A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates Fp9 PP and MVA PP in Healthy Adults Using a Prime Boost Delivery Schedule
Inventor: Prof. Adrian Hill (University of Oxford, United Kingdom)
Principal Investigator: Prof. Adrian Hill; co-investigator Dr Fiona Thompson (University of Oxford, United Kingdom)
The final report has been submitted to EMVI and the first draft of a manuscript for publication is to be submitted to EMVI for review by 1 May 2008.
A Phase IIa non-randomised controlled challenge trial:
Assessment of protection against malaria by sporozoite challenge of healthy adults vaccinated with the polyprotein malaria vaccines “FP9-PP,and MVA-PP” and control non-vaccinated volunteers
The trial has been completed, but no protection was observed in volunteers receiving the vaccine regime. The final report has been completed.